Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone781-890-0102
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees17
Next Earnings Date5/8/2019 (Estimated)
OptionableNot Optionable
Proteon Therapeutics (NASDAQ:PRTO) Frequently Asked Questions
What is Proteon Therapeutics' stock symbol?
Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."
How were Proteon Therapeutics' earnings last quarter?
Proteon Therapeutics Inc (NASDAQ:PRTO) released its quarterly earnings results on Wednesday, March, 13th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.01. View Proteon Therapeutics' Earnings History.
When is Proteon Therapeutics' next earnings date?
What price target have analysts set for PRTO?
6 brokers have issued 12-month price objectives for Proteon Therapeutics' shares. Their predictions range from $1.00 to $5.00. On average, they anticipate Proteon Therapeutics' share price to reach $3.3333 in the next twelve months. This suggests a possible upside of 693.7% from the stock's current price. View Analyst Price Targets for Proteon Therapeutics.
What is the consensus analysts' recommendation for Proteon Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteon Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Proteon Therapeutics.
What are Wall Street analysts saying about Proteon Therapeutics stock?
Here are some recent quotes from research analysts about Proteon Therapeutics stock:
- 1. According to Zacks Investment Research, "Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass. " (4/17/2019)
- 2. Maxim Group analysts commented, "Proteon announced that the second phase 3 study of vonapanitase failed to reach statistical significance on both co-primary endpoints; secondary patency and fistula use for hemodialysis. The company is evaluating its strategic options and has $16.5M in cash on the balance sheet. Shares are down sharply (~83%). We have removed vonapanitase from our model and are downgrading the shares to and removing our prior price target of $5.00 as the company explores its options." (3/28/2019)
Has Proteon Therapeutics been receiving favorable news coverage?
Media headlines about PRTO stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Proteon Therapeutics earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.
Are investors shorting Proteon Therapeutics?
Proteon Therapeutics saw a decline in short interest in April. As of April 15th, there was short interest totalling 859,256 shares, a decline of 28.6% from the March 29th total of 1,204,018 shares. Based on an average daily volume of 2,747,563 shares, the short-interest ratio is currently 0.3 days. Approximately 7.7% of the shares of the company are short sold. View Proteon Therapeutics' Current Options Chain.
Who are some of Proteon Therapeutics' key competitors?
Some companies that are related to Proteon Therapeutics include Vical (VICL), Titan Pharmaceuticals (TTNP), aTyr Pharma (LIFE), TRACON Pharmaceuticals (TCON), CytRx (CYTR), Outlook Therapeutics (OTLK), TrovaGene (TROV), Windtree Therapeutics (WINT), Aevi Genomic Medicine (GNMX), Genetic Technologies (GENE), Neuralstem (CUR), Enzon Pharmaceuticals (ENZN), Mymetics (MYMX), Vaxart (VXRT) and Mateon Therapeutics (MATN).
What other stocks do shareholders of Proteon Therapeutics own?
Who are Proteon Therapeutics' key executives?
Proteon Therapeutics' management team includes the folowing people:
- Mr. Timothy P. Noyes, Pres, CEO & Director (Age 57)
- Mr. George A. Eldridge, Sr. VP, CFO, Treasurer & Assistant Sec. (Age 56)
- Dr. Steven Keith Burke, Sr. VP & Chief Medical Officer (Age 58)
- Mr. Matthew P. Kowalsky, VP of Legal & Sec. (Age 46)
- Mr. Bradley J. Hartman, VP of People (Age 38)
Who are Proteon Therapeutics' major shareholders?
Proteon Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.30%). Company insiders that own Proteon Therapeutics stock include George Arthur Eldridge, James E Flynn and Steven Keith Burke. View Institutional Ownership Trends for Proteon Therapeutics.
Which major investors are buying Proteon Therapeutics stock?
PRTO stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Proteon Therapeutics stock in the last two years include George Arthur Eldridge, James E Flynn and Steven Keith Burke. View Insider Buying and Selling for Proteon Therapeutics.
How do I buy shares of Proteon Therapeutics?
Shares of PRTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Proteon Therapeutics' stock price today?
One share of PRTO stock can currently be purchased for approximately $0.42.
How big of a company is Proteon Therapeutics?
Proteon Therapeutics has a market capitalization of $8.23 million. The biopharmaceutical company earns $-20,730,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Proteon Therapeutics employs 17 workers across the globe.
What is Proteon Therapeutics' official website?
How can I contact Proteon Therapeutics?
Proteon Therapeutics' mailing address is 200 WEST STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 781-890-0102 or via email at [email protected]
MarketBeat Community Rating for Proteon Therapeutics (NASDAQ PRTO)
MarketBeat's community ratings are surveys of what our community members think about Proteon Therapeutics and other stocks. Vote "Outperform" if you believe PRTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTO will underperform the S&P 500 over the long term. You may vote once every thirty days.
